Daiwa Securities Group
KNTE

Daiwa Securities Group’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Daiwa Securities Group’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-127
Closed – – 1413
2023
Q3 		$0 Hold
127
– – ﹤0.01% 1352
2023
Q2 		$0 Hold
127
– – ﹤0.01% 1367
2023
Q1 		$1K Hold
127
– – ﹤0.01% 1297
2022
Q4 		$1K Hold
127
– – ﹤0.01% 1305
2022
Q3 		$2K Hold
127
– – ﹤0.01% 1256
2022
Q2 		$2K Hold
127
– – ﹤0.01% 1265
2022
Q1 		$1K Hold
127
– – ﹤0.01% 1359
2021
Q4 		$2K Buy
+127
New +$2.68K ﹤0.01% 1314

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Daiwa Securities Group's KNTE Position: Q4 2023 in Review

Daiwa Securities Group sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q4 2023, closing a stake of 127 shares.

Daiwa Securities Group first reported a position in KNTE in Q4 2021 and held it in 8 quarters. The position peaked at $2K in Q3 2022. 62 funds tracked by Wall St. Rank hold KNTE as of Q4 2023.

  • Daiwa Securities Group reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Daiwa Securities Group sold 127 Kinnate Biopharma Inc. Common Stock shares in Q4 2023.
  • Daiwa Securities Group first reported a position in Kinnate Biopharma Inc. Common Stock in Q4 2021 and held it in 8 quarters.
  • Daiwa Securities Group's Kinnate Biopharma Inc. Common Stock position peaked at $2K in Q3 2022.
  • 62 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q4 2023.

Based on Daiwa Securities Group's 13F filing for Q4 2023, filed 31 Jan 2024.